These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 19539456)

  • 21. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
    Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome and effects of oral bosentan therapy in Taiwanese patients with advanced idiopathic pulmonary arterial hypertension.
    Hsu HH; Chen JS; Chen RJ; Ko WJ; Kuo SW; Wu ET; Wu MH; Wang JK; Lee YC
    Respir Med; 2007 Jul; 101(7):1556-62. PubMed ID: 17223329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
    Diller GP; Dimopoulos K; Kaya MG; Harries C; Uebing A; Li W; Koltsida E; Gibbs JS; Gatzoulis MA
    Heart; 2007 Aug; 93(8):974-6. PubMed ID: 17639112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.
    Hoeper MM; Faulenbach C; Golpon H; Winkler J; Welte T; Niedermeyer J
    Eur Respir J; 2004 Dec; 24(6):1007-10. PubMed ID: 15572546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2005 Nov; 91(11):1447-52. PubMed ID: 15761050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
    Apostolopoulou SC; Manginas A; Cokkinos DV; Rammos S
    Heart; 2007 Mar; 93(3):350-4. PubMed ID: 16980516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease.
    Kotlyar E; Sy R; Keogh AM; Kermeen F; Macdonald PS; Hayward CS; McNeil KD; Celermajer DS
    Cardiol Young; 2006 Jun; 16(3):268-74. PubMed ID: 16725066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
    Provencher S; Sitbon O; Humbert M; Cabrol S; Jaïs X; Simonneau G
    Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.